Phaseline

Companies › Epizyme

Epizyme: clinical trials, targets and expected readouts

1 active drug program in 12 registered trials: 7 Phase 1, 4 Phase 2, 1 Phase 3; Oncology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tazemetostat
Histone-lysine N-methyltransferase EZH2 inhibitor
EZH2Phase 3Relapsed/Refractory Follicular Lymphoma; Peripheral Nerve Sheath Tumor; B-Cell Non-Hodgkin Lymphoma; Grade 3b Follicular Lymphoma …Feb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04917042TazemetostatPhase 2Peripheral Nerve Sheath TumorOncologyDec 2026
NCT04846478TazemetostatPhase 1Metastatic Prostate CancerOncologyDec 2026
NCT05407441TazemetostatPhase 1Atypical Teratoid Rhabdoid TumorOncologyFeb 2027
NCT04224493TazemetostatPhase 3Relapsed/Refractory Follicular LymphomaOncologyFeb 2027
NCT06242834TazemetostatPhase 2B-Cell Non-Hodgkin LymphomaOncologyApr 2027
NCT05551936TazemetostatPhase 1Follicular LymphomaOncologyMay 2027
NCT05627232TazemetostatPhase 1Recurrent Acute Myeloid LeukemiaOncologyJan 2028
NCT02889523TazemetostatPhase 1LymphomaOncologySep 2029
NCT05890352TazemetostatPhase 2Grade 3b Follicular LymphomaOncologyDec 2029
NCT05934838TazemetostatPhase 1Follicular LymphomaOncologySep 2031
NCT06824701TazemetostatPhase 1Relapsed or Refractory B-cell Non-Hodgkin LymphomaOncologyJan 2032
NCT05994235TazemetostatPhase 2Follicular LymphomaOncologyOct 2033

Targets

EZH2 (1)

Companies with the same targets

Novartis Evopoint Biosciences Daiichi Sankyo Hanmi Pharmaceutical Company

Companies built like this

Maia Biotechnology K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals FutureGen Biopharmaceutical (Beijing) CanariaBio pharmaand

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.